Improved	O
adipose	B:C0001527
tissue	I:C0001527
function	O
with	O
initiation	O
of	O
protease	B:C0033607
inhibitor	I:C0033607
-	O
only	O
ART	B:C1963724
.	O

Use	O
of	O
ART	B:C1963724
containing	O
HIV	B:C3536912
PIs	I:C3536912
has	O
previously	O
been	O
associated	O
with	O
toxicity	B:C0600688
in	O
subcutaneous	B:C0222331
adipose	I:C0222331
tissue	I:C0222331
(	O
subcutaneous	B:C0222331
adipose	I:C0222331
tissue	I:C0222331
)	O
,	O
potentially	O
contributing	O
to	O
the	O
development	O
of	O
lipodystrophy	B:C0023787
and	O
insulin	B:C0021655
resistance	I:C0021655
.	O

However	O
,	O
the	O
effect	O
of	O
PIs	B:C0033607
on	O
subcutaneous	B:C0222331
adipose	I:C0222331
tissue	I:C0222331
function	O
in	O
ART	B:C1963724
-	O
naive	B:C0919936
patients	O
independent	O
of	O
other	O
ART	B:C1963724
classes	O
is	O
unknown	O
.	O

This	O
study	O
aimed	O
to	O
elucidate	O
the	O
effect	O
of	O
initiating	O
PI	B:C0033607
-	O
only	O
ART	B:C1963724
on	O
subcutaneous	B:C0222331
adipose	I:C0222331
tissue	I:C0222331
function	O
in	O
ART	B:C1963724
-	O
naive	B:C0919936
subjects	O
.	O

In	O
the	O
HIVNAT	B:C0242481
-	I:C0242481
019	I:C0242481
study	I:C0242481
,	O
48	O
HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
,	O
ART	B:C1963724
-	O
naive	B:C0919936
Thai	B:C0337910
adults	O
commencing	O
PI	B:C0033607
-	O
only	O
ART	B:C1963724
comprising	O
lopinavir	B:C0674432
/	O
ritonavir	B:C0292818
/	O
saquinavir	B:C0286738
for	O
24	O
weeks	O
underwent	O
assessments	B:C1261322
of	O
fasting	B:C0015663
metabolic	B:C0025519
parameters	O
and	O
body	O
composition	O
.	O

In	O
a	O
molecular	O
substudy	B:C4288169
,	O
20	O
subjects	O
underwent	O
subcutaneous	B:C0222331
adipose	I:C0222331
tissue	I:C0222331
biopsies	B:C0005558
at	O
weeks	O
0	O
,	O
2	O
and	O
24	O
for	O
transcriptional	B:C0040649
,	O
protein	B:C1514534
,	O
mitochondrial	B:C0012929
DNA	I:C0012929
(	O
mitochondrial	B:C0012929
DNA	I:C0012929
)	O
and	O
histological	B:C0344441
analyses	I:C0344441
.	O

ClinicalTrials.gov	B:C0008976
registration	I:C0008976
number	I:C0008976
:	I:C0008976
NCT00400738	I:C0008976
.	O

Over	O
24	O
weeks	O
,	O
limb	B:C0243095
fat	I:C0243095
increased	I:C0243095
(	O
+416.4	O
g	O
,	O
P	O
=	O
0.023	O
)	O
,	O
coinciding	O
with	O
larger	O
adipocytes	B:C0206131
as	O
indicated	B:C1444656
by	O
decreased	O
adipocyte	B:C0206131
density	O
in	O
biopsies	B:C0005558
(	O
-	O
32.3	O
cells	B:C0007634
/	O
mm	O
(	O
2	O
)	O
,	O
P	O
=	O
0.047	O
)	O
and	O
increased	O
mRNA	B:C1515670
expression	I:C1515670
of	O
adipogenesis	B:C0596843
regulator	B:C1152862
PPARG	B:C1335238
at	O
week	O
2	O
(	O
+58.1	O
%	O
,	O
P	O
=	O
0.003	O
)	O
.	O

Increases	O
in	O
mitochondrial	B:C0012929
DNA	I:C0012929
over	O
24	O
weeks	O
(	O
+600	O
copies	O
/	O
cell	O
,	O
P	O
=	O
0.041	O
)	O
,	O
decreased	O
NRF1	B:C1417846
mRNA	B:C1515670
expression	I:C1515670
at	O
week	O
2	O
(	O
-	O
33.7	O
%	O
,	O
P	O
<	O
0.001	O
)	O
and	O
increased	O
COX2	B:C1565860
/	O
COX4	B:C0033684
protein	I:C0033684
ratio	O
at	O
week	O
24	O
(	O
+288	O
%	O
,	O
P	O
=	O
0.038	O
)	O
indicated	B:C1444656
improved	O
mitochondrial	B:C0026237
function	B:C0007613
.	O

Despite	O
decreased	O
AKT2	B:C0812230
mRNA	B:C0035696
at	O
week	O
2	O
(	O
-	O
28.6	O
%	O
,	O
P	O
=	O
0.002	O
)	O
and	O
increased	O
PTPN1	B:C1335281
mRNA	B:C0035696
at	O
week	O
24	O
(	O
+50.3	O
%	O
,	O
P	O
=	O
0.016	O
)	O
suggesting	O
insulin	B:C0021655
resistance	I:C0021655
,	O
clinical	O
insulin	B:C0920563
sensitivity	I:C0920563
[	O
by	O
homeostasis	B:C1829779
model	I:C1829779
assessment	I:C1829779
(	O
HOMA	B:C1829779
-	I:C1829779
IR	I:C1829779
)	O
]	O
was	O
unchanged	B:C0442739
.	O

Initiation	O
of	O
PI	B:C0033607
-	O
only	O
ART	B:C1963724
showed	O
little	O
evidence	O
of	O
subcutaneous	B:C0222331
adipose	I:C0222331
tissue	I:C0222331
toxicity	B:C0600688
,	O
the	O
changes	O
observed	O
being	O
consistent	O
with	O
a	O
return	O
to	O
health	O
rather	O
than	O
contributing	O
to	O
lipodystrophy	B:C0023787
.	O

